Loading…
Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers
Background Albuterol is the most commonly used β agonist to treat reversible lower airway obstruction. Albuterol contains a racemic mixture of two enantiomers. Levalbuterol contains the single R form enantiomer. Levalbuterol is frequently prescribed to limit cardiovascular toxicity. Objective We exa...
Saved in:
| Published in: | Lung 2017-04, Vol.195 (2), p.233-239 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c530t-a1d7de130959564251b01fe58327ee950607948b978cfa2ba652d2df81cc2e593 |
| container_end_page | 239 |
| container_issue | 2 |
| container_start_page | 233 |
| container_title | Lung |
| container_volume | 195 |
| creator | Virk, Manpreet K. Hotz, Justin Khemani, Robinder G. Newth, Christopher J. L. Ross, Patrick A. |
| description | Background
Albuterol is the most commonly used β agonist to treat reversible lower airway obstruction. Albuterol contains a racemic mixture of two enantiomers. Levalbuterol contains the single R form enantiomer. Levalbuterol is frequently prescribed to limit cardiovascular toxicity.
Objective
We examined changes in oxygen consumption (V’O
2
) and heart rate (HR) following administration of albuterol and levalbuterol.
Methods
This is a prospective, randomized, single-blinded, controlled study of healthy adult volunteers. Subjects separately received albuterol (5 mg) and levalbuterol (2.5 mg) aerosolized over 15 min. V’O
2
and vital signs were measured before the medications and 5, 10, 20, 40, and 60 min after.
Results
We enrolled 24 volunteers with a median age of 32 years. Compared to baseline, there was a significant maximum increase in V’O
2
following administration of both albuterol (median 17% (1, 3 IQR 9, 43%)
p
|
| doi_str_mv | 10.1007/s00408-017-9982-8 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1869965936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A550951268</galeid><sourcerecordid>A550951268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-a1d7de130959564251b01fe58327ee950607948b978cfa2ba652d2df81cc2e593</originalsourceid><addsrcrecordid>eNp1kkFv1DAQhS0EokvhB3BBkZAQFxfbiRP7uIoorbRSL8DVcpLJxpVjL3ZCWX49TrfAFi3ywdLM90ajNw-h15RcUEKqD5GQgghMaIWlFAyLJ2hFi5xhWnHyFK1IXlDMEnOGXsR4SxJYUv4cnTHBKBFErNDPetBuC5lx2c2P_RZcVnsX53E3Ge-yS2-tvzNum127QVt9X_R9trbNPEHwdtHVftzpYGJq3ZlpyDbwXR_3r0Dbadhn6262U_bV29lNACG-RM96bSO8evjP0ZfLj5_rK7y5-XRdrze45TmZsKZd1QHNieSSlwXjtCG0By5yVgFITkpSyUI0shJtr1mjS8461vWCti0DLvNz9P4wdxf8txnipEYTW7BWO_BzVFSUUpYJLBP69h_01s_Bpe0SJUqW_GPFX2qrLSjjej8F3S5D1ZrztCdlpUgUPkElhyFo6x30JpUf8Rcn-PQ6GE17UvDuSDDcuxyTu8uR4mOQHsA2-BgD9GoXzKjDXlGiliCpQ5BUyodagqQWzZsHJ-ZmhO6P4ndyEsAOQEytlKBwZNV_p_4C4x7QsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1886217624</pqid></control><display><type>article</type><title>Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers</title><source>Springer Link</source><creator>Virk, Manpreet K. ; Hotz, Justin ; Khemani, Robinder G. ; Newth, Christopher J. L. ; Ross, Patrick A.</creator><creatorcontrib>Virk, Manpreet K. ; Hotz, Justin ; Khemani, Robinder G. ; Newth, Christopher J. L. ; Ross, Patrick A.</creatorcontrib><description>Background
Albuterol is the most commonly used β agonist to treat reversible lower airway obstruction. Albuterol contains a racemic mixture of two enantiomers. Levalbuterol contains the single R form enantiomer. Levalbuterol is frequently prescribed to limit cardiovascular toxicity.
Objective
We examined changes in oxygen consumption (V’O
2
) and heart rate (HR) following administration of albuterol and levalbuterol.
Methods
This is a prospective, randomized, single-blinded, controlled study of healthy adult volunteers. Subjects separately received albuterol (5 mg) and levalbuterol (2.5 mg) aerosolized over 15 min. V’O
2
and vital signs were measured before the medications and 5, 10, 20, 40, and 60 min after.
Results
We enrolled 24 volunteers with a median age of 32 years. Compared to baseline, there was a significant maximum increase in V’O
2
following administration of both albuterol (median 17% (1, 3 IQR 9, 43%)
p
< 0.001) and levalbuterol (median 23% (1, 3 IQR 10, 32%)
p
< 0.001). There was no significant difference between the maximum increase in V’O
2
following administration of albuterol compared to levalbuterol (
p
= 0.57). Compared to baseline, there was a significant maximal increase in HR with both albuterol (median 30% (1, 3 IQR 19, 43%)
p
< 0.001) and levalbuterol (median 23% (1, 3 IQR 19, 31%)
p
< 0.001). There was a statistically significant greater increase in maximal HR following administration of albuterol as compared to levalbuterol (
p
= 0.009).
Conclusion
Albuterol and levalbuterol both cause a significant increase in V’O
2
and HR. There was no significant difference between albuterol and levalbuterol regarding the maximum increase in V’O
2
. There was a statistically significant but likely clinically insignificant difference in maximum increase in HR in patients with adequate oxygen delivery when comparing albuterol to levalbuterol.</description><identifier>ISSN: 0341-2040</identifier><identifier>EISSN: 1432-1750</identifier><identifier>DOI: 10.1007/s00408-017-9982-8</identifier><identifier>PMID: 28210808</identifier><identifier>CODEN: LUNGD9</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Administration, Inhalation ; Adult ; Albuterol - administration & dosage ; Albuterol - pharmacology ; Asthma ; Bronchodilator Agents - administration & dosage ; Bronchodilator Agents - pharmacology ; Drug therapy ; Healthy Volunteers ; Heart rate ; Heart Rate - drug effects ; Humans ; Levalbuterol - administration & dosage ; Levalbuterol - pharmacology ; Medicine ; Medicine & Public Health ; Middle Aged ; Oxygen ; Oxygen Consumption - drug effects ; Pneumology/Respiratory System ; Prospective Studies ; Respiratory therapy ; Single-Blind Method ; Young Adult</subject><ispartof>Lung, 2017-04, Vol.195 (2), p.233-239</ispartof><rights>Springer Science+Business Media New York 2017</rights><rights>COPYRIGHT 2017 Springer</rights><rights>Lung is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c530t-a1d7de130959564251b01fe58327ee950607948b978cfa2ba652d2df81cc2e593</cites><orcidid>0000-0002-1458-1526</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28210808$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Virk, Manpreet K.</creatorcontrib><creatorcontrib>Hotz, Justin</creatorcontrib><creatorcontrib>Khemani, Robinder G.</creatorcontrib><creatorcontrib>Newth, Christopher J. L.</creatorcontrib><creatorcontrib>Ross, Patrick A.</creatorcontrib><title>Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers</title><title>Lung</title><addtitle>Lung</addtitle><addtitle>Lung</addtitle><description>Background
Albuterol is the most commonly used β agonist to treat reversible lower airway obstruction. Albuterol contains a racemic mixture of two enantiomers. Levalbuterol contains the single R form enantiomer. Levalbuterol is frequently prescribed to limit cardiovascular toxicity.
Objective
We examined changes in oxygen consumption (V’O
2
) and heart rate (HR) following administration of albuterol and levalbuterol.
Methods
This is a prospective, randomized, single-blinded, controlled study of healthy adult volunteers. Subjects separately received albuterol (5 mg) and levalbuterol (2.5 mg) aerosolized over 15 min. V’O
2
and vital signs were measured before the medications and 5, 10, 20, 40, and 60 min after.
Results
We enrolled 24 volunteers with a median age of 32 years. Compared to baseline, there was a significant maximum increase in V’O
2
following administration of both albuterol (median 17% (1, 3 IQR 9, 43%)
p
< 0.001) and levalbuterol (median 23% (1, 3 IQR 10, 32%)
p
< 0.001). There was no significant difference between the maximum increase in V’O
2
following administration of albuterol compared to levalbuterol (
p
= 0.57). Compared to baseline, there was a significant maximal increase in HR with both albuterol (median 30% (1, 3 IQR 19, 43%)
p
< 0.001) and levalbuterol (median 23% (1, 3 IQR 19, 31%)
p
< 0.001). There was a statistically significant greater increase in maximal HR following administration of albuterol as compared to levalbuterol (
p
= 0.009).
Conclusion
Albuterol and levalbuterol both cause a significant increase in V’O
2
and HR. There was no significant difference between albuterol and levalbuterol regarding the maximum increase in V’O
2
. There was a statistically significant but likely clinically insignificant difference in maximum increase in HR in patients with adequate oxygen delivery when comparing albuterol to levalbuterol.</description><subject>Administration, Inhalation</subject><subject>Adult</subject><subject>Albuterol - administration & dosage</subject><subject>Albuterol - pharmacology</subject><subject>Asthma</subject><subject>Bronchodilator Agents - administration & dosage</subject><subject>Bronchodilator Agents - pharmacology</subject><subject>Drug therapy</subject><subject>Healthy Volunteers</subject><subject>Heart rate</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Levalbuterol - administration & dosage</subject><subject>Levalbuterol - pharmacology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oxygen</subject><subject>Oxygen Consumption - drug effects</subject><subject>Pneumology/Respiratory System</subject><subject>Prospective Studies</subject><subject>Respiratory therapy</subject><subject>Single-Blind Method</subject><subject>Young Adult</subject><issn>0341-2040</issn><issn>1432-1750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kkFv1DAQhS0EokvhB3BBkZAQFxfbiRP7uIoorbRSL8DVcpLJxpVjL3ZCWX49TrfAFi3ywdLM90ajNw-h15RcUEKqD5GQgghMaIWlFAyLJ2hFi5xhWnHyFK1IXlDMEnOGXsR4SxJYUv4cnTHBKBFErNDPetBuC5lx2c2P_RZcVnsX53E3Ge-yS2-tvzNum127QVt9X_R9trbNPEHwdtHVftzpYGJq3ZlpyDbwXR_3r0Dbadhn6262U_bV29lNACG-RM96bSO8evjP0ZfLj5_rK7y5-XRdrze45TmZsKZd1QHNieSSlwXjtCG0By5yVgFITkpSyUI0shJtr1mjS8461vWCti0DLvNz9P4wdxf8txnipEYTW7BWO_BzVFSUUpYJLBP69h_01s_Bpe0SJUqW_GPFX2qrLSjjej8F3S5D1ZrztCdlpUgUPkElhyFo6x30JpUf8Rcn-PQ6GE17UvDuSDDcuxyTu8uR4mOQHsA2-BgD9GoXzKjDXlGiliCpQ5BUyodagqQWzZsHJ-ZmhO6P4ndyEsAOQEytlKBwZNV_p_4C4x7QsQ</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Virk, Manpreet K.</creator><creator>Hotz, Justin</creator><creator>Khemani, Robinder G.</creator><creator>Newth, Christopher J. L.</creator><creator>Ross, Patrick A.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1458-1526</orcidid></search><sort><creationdate>20170401</creationdate><title>Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers</title><author>Virk, Manpreet K. ; Hotz, Justin ; Khemani, Robinder G. ; Newth, Christopher J. L. ; Ross, Patrick A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-a1d7de130959564251b01fe58327ee950607948b978cfa2ba652d2df81cc2e593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Inhalation</topic><topic>Adult</topic><topic>Albuterol - administration & dosage</topic><topic>Albuterol - pharmacology</topic><topic>Asthma</topic><topic>Bronchodilator Agents - administration & dosage</topic><topic>Bronchodilator Agents - pharmacology</topic><topic>Drug therapy</topic><topic>Healthy Volunteers</topic><topic>Heart rate</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Levalbuterol - administration & dosage</topic><topic>Levalbuterol - pharmacology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oxygen</topic><topic>Oxygen Consumption - drug effects</topic><topic>Pneumology/Respiratory System</topic><topic>Prospective Studies</topic><topic>Respiratory therapy</topic><topic>Single-Blind Method</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Virk, Manpreet K.</creatorcontrib><creatorcontrib>Hotz, Justin</creatorcontrib><creatorcontrib>Khemani, Robinder G.</creatorcontrib><creatorcontrib>Newth, Christopher J. L.</creatorcontrib><creatorcontrib>Ross, Patrick A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Lung</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Virk, Manpreet K.</au><au>Hotz, Justin</au><au>Khemani, Robinder G.</au><au>Newth, Christopher J. L.</au><au>Ross, Patrick A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers</atitle><jtitle>Lung</jtitle><stitle>Lung</stitle><addtitle>Lung</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>195</volume><issue>2</issue><spage>233</spage><epage>239</epage><pages>233-239</pages><issn>0341-2040</issn><eissn>1432-1750</eissn><coden>LUNGD9</coden><abstract>Background
Albuterol is the most commonly used β agonist to treat reversible lower airway obstruction. Albuterol contains a racemic mixture of two enantiomers. Levalbuterol contains the single R form enantiomer. Levalbuterol is frequently prescribed to limit cardiovascular toxicity.
Objective
We examined changes in oxygen consumption (V’O
2
) and heart rate (HR) following administration of albuterol and levalbuterol.
Methods
This is a prospective, randomized, single-blinded, controlled study of healthy adult volunteers. Subjects separately received albuterol (5 mg) and levalbuterol (2.5 mg) aerosolized over 15 min. V’O
2
and vital signs were measured before the medications and 5, 10, 20, 40, and 60 min after.
Results
We enrolled 24 volunteers with a median age of 32 years. Compared to baseline, there was a significant maximum increase in V’O
2
following administration of both albuterol (median 17% (1, 3 IQR 9, 43%)
p
< 0.001) and levalbuterol (median 23% (1, 3 IQR 10, 32%)
p
< 0.001). There was no significant difference between the maximum increase in V’O
2
following administration of albuterol compared to levalbuterol (
p
= 0.57). Compared to baseline, there was a significant maximal increase in HR with both albuterol (median 30% (1, 3 IQR 19, 43%)
p
< 0.001) and levalbuterol (median 23% (1, 3 IQR 19, 31%)
p
< 0.001). There was a statistically significant greater increase in maximal HR following administration of albuterol as compared to levalbuterol (
p
= 0.009).
Conclusion
Albuterol and levalbuterol both cause a significant increase in V’O
2
and HR. There was no significant difference between albuterol and levalbuterol regarding the maximum increase in V’O
2
. There was a statistically significant but likely clinically insignificant difference in maximum increase in HR in patients with adequate oxygen delivery when comparing albuterol to levalbuterol.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28210808</pmid><doi>10.1007/s00408-017-9982-8</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1458-1526</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0341-2040 |
| ispartof | Lung, 2017-04, Vol.195 (2), p.233-239 |
| issn | 0341-2040 1432-1750 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1869965936 |
| source | Springer Link |
| subjects | Administration, Inhalation Adult Albuterol - administration & dosage Albuterol - pharmacology Asthma Bronchodilator Agents - administration & dosage Bronchodilator Agents - pharmacology Drug therapy Healthy Volunteers Heart rate Heart Rate - drug effects Humans Levalbuterol - administration & dosage Levalbuterol - pharmacology Medicine Medicine & Public Health Middle Aged Oxygen Oxygen Consumption - drug effects Pneumology/Respiratory System Prospective Studies Respiratory therapy Single-Blind Method Young Adult |
| title | Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A40%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Change%20in%20Oxygen%20Consumption%20Following%20Inhalation%20of%20Albuterol%20in%20Comparison%20with%20Levalbuterol%20in%20Healthy%20Adult%20Volunteers&rft.jtitle=Lung&rft.au=Virk,%20Manpreet%20K.&rft.date=2017-04-01&rft.volume=195&rft.issue=2&rft.spage=233&rft.epage=239&rft.pages=233-239&rft.issn=0341-2040&rft.eissn=1432-1750&rft.coden=LUNGD9&rft_id=info:doi/10.1007/s00408-017-9982-8&rft_dat=%3Cgale_proqu%3EA550951268%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c530t-a1d7de130959564251b01fe58327ee950607948b978cfa2ba652d2df81cc2e593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1886217624&rft_id=info:pmid/28210808&rft_galeid=A550951268&rfr_iscdi=true |